Cookie policy: This site uses cookies (small files stored on your computer) to simplify and improve your experience of this website. Cookies are small text files stored on the device you are using to access this website. For more information please take a look at our terms and conditions. Some parts of the site may not work properly if you choose not to accept cookies.


Subscribe or Register

Existing user? Login

Paracetamol infusion given the green light in Scotland

Paracetamol infusion (Perfalgan), launched last year (PJ, 24 April 2004, p498), has been given the green light for use within NHS Scotland by the Scottish Medicines Consortium.

In guidance issued last month, the SMC also recommended that four other products be accepted for use:

· Rosiglitazone maleate/metformin hydrochloride (Avandamet) for type 2 diabetes
· Rituximab (MabThera) for stage III-IV follicular lymphoma
· Etomidate (Lipuro) for general anaesthesia
· Miglustat (Zavesca) for Type 1 Gaucher’s disease

Laronidase (Aldurazyme), a product used for mucopolysaccharidosis I and granted orphan drug status by European regulators, was not approved for use by the SMC.
Products approved for restricted use were:

· Creon micro (Creon) for pancreatic exocrine insufficiency in infants unable to swallow capsules
· Eplerenone (Inspra) for cardiovascular
disease in patients with left ventricular dysfunction who cannot tolerate
· Voriconazole (Vfend) for invasive fungal infections primarily in immunocompromised patients with progressive, possibly life-threatening infections
· Ertapenem (Invanz) as second- or third-line treatment of adults with community acquired abdominal infections resistant to conventional treatments

Citation: The Pharmaceutical Journal URI: 10018198

Have your say

For commenting, please login or register as a user and agree to our Community Guidelines. You will be re-directed back to this page where you will have the ability to comment.

Recommended from Pharmaceutical Press

Search an extensive range of the world’s most trusted resources

Powered by MedicinesComplete
  • Print
  • Share
  • Comment
  • Save
  • Print Friendly Version of this pagePrint Get a PDF version of this webpagePDF

Newsletter Sign-up

Want to keep up with the latest news, comment and CPD articles in pharmacy and science? Subscribe to our free alerts.